Reps. David McKinley (R-WV) and Mike Thompson (D-CA) last night introduced H.R. 4392, a bill that would prevent a dramatic reduction in Medicare Part B payments for certain hospitals that participate in the 340B Drug Pricing Program. The Centers for Medicare & Medicaid Services recently released a final rule that reduces by nearly 30%, or $1.6 billion, Medicare payments to certain public and non-profit hospitals for outpatient drugs purchased under the 340B program. “The AHA thanks Representatives McKinley and Thompson for leading this bipartisan effort to protect patient care by preventing CMS from reducing Medicare Part B payments for some 340B hospitals,” said AHA Executive Vice President Tom Nickels. “For 25 years, the 340B program has been critical in helping hospitals expand access to lifesaving prescription drugs and comprehensive health care to low-income patients and other vulnerable populations in communities across the country.” The AHA, joined by the Association of American Medical Colleges and America's Essential Hospitals, Nov. 13 filed a federal lawsuit to prevent CMS from implementing these cuts.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services Sept. 18 released a final rule on policy and technical changes to Medicare Advantage, the Medicare…
Headline
The AHA submitted a statement Sept. 17 for a House Ways and Means Committee markup session on a series of health care and other bills. Specifically, the AHA…
Headline
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
The AHA Sept. 15 expressed support for the Ensuring Access to Essential Providers Act, legislation that would require Medicare Advantage plans to cover…
Headline
The AHA Sept. 15 urged Aetna to rescind its recently announced “level of severity inpatient payment” policy, saying that it “could erode the transparency…
Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…